, whose active ingredient is Clozapine, generated about $34 million in U.
Since completing the acquisition of Alamo, the company has recorded as net deferred revenues wholesaler shipments for FazaClo totaling $4.
FazaClo is also indicated for reducing the risk of suicidal behavior in patients with schizophrenic or schizoaffective disorder.
Completed the previously announced sale of FazaClo to Azur Pharma Inc.
Total net revenues from continuing operations for fiscal 2007 (excluding FazaClo net revenues) were $9.
The Company believes that the net proceeds from the sale of FazaClo
, plus the cash, cash equivalents and unrestricted investments in securities at June 30, 2007 will be sufficient to finance operating expenses through the end of the next fiscal year, including the planned initiation of the confirmatory Phase III clinical trial of Zenvia in patients with PBA/IEED.
AVANIR will finalize the transfer of FazaClo
business operations to Azur Pharma in the coming months.
AVANIR has agreed to transfer or assign all FazaClo
business operations including marketing, sales and medical affairs infrastructure as well as manufacturing agreements to Azur Pharma following the completion of the transaction.
was only available in 25 mg and 100 mg dosage strengths in special blister packaging.
Reported that the Company is in discussions with several parties that have expressed interest in potentially acquiring certain Company assets, including FazaClo
and several investigational compounds.
net wholesaler shipments for the quarter ended March 31, 2007 were approximately $4.
ziconotide) intrathecal infusion, Versacloz(TM) (clozapine) oral suspension, FazaClo
(clozapine, USP) HD and FazaClo
Announced receipt of an approvable letter from the FDA for a new formulation of its currently marketed antipsychotic drug FazaClo